Avalo Therapeutics AVTX Deferred Taxes
Deferred Taxes at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's deferred taxes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's deferred taxes?
- Avalo Therapeutics (AVTX) reported deferred taxes of $446K in Q1 2026.
- How has Avalo Therapeutics's deferred taxes changed year-over-year?
- Avalo Therapeutics's deferred taxes increased by 60.4% year-over-year, from $278K to $446K.
- What is the long-term trend for Avalo Therapeutics's deferred taxes?
- Over 5 years (2020 to 2025), Avalo Therapeutics's deferred taxes has grown at a 37.0% compound annual growth rate (CAGR), from $90K to $434K.
- What does deferred taxes mean?
- This represents the net amount of income taxes that will be payable in future periods due to temporary differences between the carrying amount of assets and liabilities for financial reporting and their tax bases. It reflects the long-term tax impact of accounting choices and depreciation schedules. Investors use this to understand future tax obligations and the impact of tax timing on cash flow.